Article Information
History
- October 1, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Wouter Peelaerts1,2,*,
- Liza Bergkvist1,#,*,
- Sonia George1,
- Michaela Johnson1,
- Lindsay Meyerdirk1,
- Emily Ku,
- Jennifer A. Steiner1,
- Zachary Madaj3,
- Jiyan Ma1,
- Katelyn Becker1,
- K. Peter R. Nilsson4,
- Jerry Colca5 and
- Patrik Brundin1,†
- 1Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA
- 2KU Leuven, Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, Leuven, Belgium
- 3Bioinformatics and Biostatistics Core, Van Andel Institute, Grand Rapids, MI, USA
- 4Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden
- 5Metabolic Solutions Development Company, Kalamazoo, MI, USA
- ↵†Corresponding author: Patrik Brundin, Email: Patrik.Brundin{at}vai.org
↵* these authors contributed equally to this work
Posted October 01, 2020.
Inhibiting the mitochondrial pyruvate carrier does not ameliorate synucleinopathy in the absence of inflammation or metabolic deficits
